Nephrology CME

Credits: 1.00 CME
PeerView Institute
Advances in the Treatment of Alzheimer’s Disease: Preparing for a Shift in the Treatment Paradigm
Richard S. Isaacson, MD, FAAN
November 24, 2020
Credits: 1.00 CME
PeerView Institute
How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology
David F. McDermott, MD
November 20, 2020
Credits: 1.50
PeerView Institute
Emergency Department on Alert: Solving Oncologic Emergency Quandaries During the Immuno-Oncology Era and COVID-19 Pandemic
Jarushka Naidoo, MB, BCH, MHS
November 20, 2020
Credits: 1.00
PeerView Institute
Solutions for Tenosynovial Giant Cell Tumors: Employing Effective Multimodal and Multidisciplinary Approaches to Patient Care
Kristen Ganjoo, MD
November 19, 2020
Credits: 1.00 CME
Joslin Diabetes Center
Highlighting the Vital Role of Primary Care in Identifying and Optimizing the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Andrew Moshfeghi, MD, MBA
November 18, 2020
Credits: 1.00 CME
PeerView Institute
Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors
Hani M. Babiker, MD
November 12, 2020
Credits: 1.50
PeerView Institute
Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks, and Considerations for Decision-Making in Managed Care Settings
Kathleen N. Moore, MD, MS / Kristi Jhangiani, PharmD, BCPS
November 6, 2020
Credits: 1.00 CME
PeerView Institute
Progressive Pathways: Recent Recommendations and Emerging Therapies for Treating NF1-Associated Tumors
Roger J. Packer, MD
November 5, 2020
Credits: 0.50 CME
Penn State College of Medicine
Show Me the Data: Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DM
George L. Bakris, MD
November 2, 2020
Credits: 1.00 CME
PeerView Institute
The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC
October 28, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents
Toni K. Choueiri, MD
October 22, 2020
Credits: 1.25 CME / MOC / CNE
Medical Learning Institute, Inc.
Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse
Jay B. Wish, MD
October 5, 2020
Credits: 0.50 CME / CPE
Medical Learning Institute, Inc.
Visualizing the Potential Role of HIF-PH Inhibitors in the Treatment of Anemia in Chronic Kidney Disease
Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN
October 5, 2020
Credits: 1.00 CME
Penn State College of Medicine
Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases
John B. Buse, MD, PhD
July 24, 2020
Credits: 1.00 CME / MOC / CNE / CPE
Medical Learning Institute, Inc.
Finding the Path to Clinically Meaningful Outcomes Among Expanding Treatment Options in Renal Cell Carcinoma
Hans J. Hammers, MD, PhD
June 18, 2020
Medical Learning Institute, Inc.
How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
Toni K. Choueiri, MD
December 31, 2019
Medical Learning Institute, Inc.
Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease
Jay B. Wish, MD
December 31, 2019
Purdue University
Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors
Matthew R. Weir, MD
December 18, 2019

Pages